Sumitomo to co-promote SC Ozempic in Japan

30 May 2025

Japanese drugmaker Sumitomo Pharma (TYO: 4506) and Denmark’s Novo Nordisk (NOV: N) have entered into a co-promotion agreement in Japan for Ozempic (semaglutide) Subcutaneous Injection 2mg, a once-weekly subcutaneous GLP-1 receptor agonist indicated for the treatment of type 2 diabetes.

Ozempic has been marketed since June 2020 by Novo Nordisk’s local unit in Japan. Under this new accord, Novo Nordisk Pharma will be responsible for maintenance of the marketing approval as well as manufacture and supply of the product and Novo Nordisk Pharma and Sumitomo Pharma will jointly initiate to promoting the product to healthcare professionals in July 2025.

The Japan semaglutide market generated a revenue of $255.7 million in 2024 and is expected to reach 1,890.7 million by 2035, according to Grand View Research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK